Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors
01:30pESMO 2020 : Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial
PU
01:24pPETRONOR E&P : Agreement with The Gambia
AQ
01:22pACTBLUE : Ginsburg's death draws big surge of donations to Democrats
AQ
01:21pACTBLUE : Ginsburg's death draws big surge of donations to Democrats
AQ
01:07pROLLS ROYCE : plans to raise about 2.5 billion pounds - FT
RE
01:05pASTRAZENECA : TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
BU
12:39pASTRAZENECA : says Tagrisso shown to slow lung cancer spreading to brain
RE
12:32pBRISTOL MYERS SQUIBB : Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
BU
12:31pESMO 2020 : Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
BU
12:01pMEDIA AVAILABILITY : CN Police officers available for media interviews during Rail Safety Week
AQ
12:01pMEDIA AVAILABILITY : CN Police officers available for media interviews during Rail Safety Week
GL
11:54aROLLS ROYCE : plans to raise about 2.5 billion stg - FT
RE
11:47aROLLS ROYCE : plans to raise about 2.5 bln stg - FT
RE
11:45aIMMUNOMEDICS : Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
PU
11:45aIMMUNOMEDICS : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvyᵀᴹ in Metastatic Urothelial Cancer
PU
Discover
11:15aINFO EDGE INDIA : Investor Conference
PU
11:14aNSP Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Insperity Inc.
GL
11:01aIMMUNOMEDICS : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
AQ
11:01aImmunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
GL
10:45aROCHE : presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
PU
10:31aIMMUNOMEDICS : Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
AQ
10:31aTrodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
GL
10:30aIMMUNOMEDICS : drug Trodelvy extends survival in breast cancer patients
RE
10:25aNovartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
GL
10:21aROCHE : presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
AQ
10:21aMERCK : KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
BU
10:21aGENENTECH : Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
BU
10:20aNovartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
GL
10:20aRoche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
GL
09:16aCOSTA'S CRUISES RETURN TO GENOA : Costa Diadema Sails Today
PR
09:00aWIIT S P A : myLoc acquisition
PU
08:55aAnnouncing Killer Mike as Keynote Speaker at UNCF/Koch Scholars Program Virtual Summit
GL
08:45aNew Crop of Covid-Tracking Apps Addresses Old Concerns
DJ
08:06aITERA : Grief As Kyerwa Pays Last Respects to Deceased Children
AQ
08:00aWALMART : Amazon among donors to QAnon-promoting lawmaker
AQ
07:58aBASEBALL : Pacific League standings (Sept. 19)
AQ
07:43aTaiwan travellers take sightseeing 'flight to nowhere'
RE
07:31aZAI LAB : Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
AQ
07:31aPhase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
GL
07:15aAlibaba and Tencent Kick the Tires on a New Idea -- Keeping China's Jalopies on the Road
DJ
06:45aSTANDARD CHARTERED : We've completed our first cross-bank Letter of Credit blockchain transaction between Vietnam and Thailand
PU
06:25aG20 Trade and Investment Ministers Meeting - Press Release
PU
06:25aJSE : TEST JSE Regulatory Announcement
PU
05:20aMARSHAL LION FINANCIAL GROUP CORP : A Marshal Lion mobile app has reached many users' smartphones in record time.
EQ
04:51aPFIZER : Correction to Midwest Coronavirus Case Numbers Article on Sept. 18
DJ
03:00aAxion Receives Petition to the Court and Notice of Civil Claim
NE
02:53aTESLA : Judge narrows Tesla lawsuit against former employee, dismisses defamation counterclaim
RE
02:48aU.S. approves Anheuser-Busch deal to buy Craft Brew Alliance
RE
02:48aKEYWORDS : Moore's Law Is Dead. Long Live Huang's Law. -- WSJ
DJ
1  2  3  4  5  6  7  8  9  10Next